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Abstract
Aim: In developing African nations, late presentation and occurrence of complications adversely affects survival. This 
study aims at identifying initial clinical and basic laboratory features of multiple myeloma (MM), which will aid the physician 
to entertain a high index of suspicion and therefore target his investigations in order to prevent late presentation and 
avert complications.
Materials and Methods: A retrospective analysis of 32 patients diagnosed and managed in Nigeria, West Africa was 
done. Information on the clinical, laboratory, and radiological data as well as response to treatment was obtained at 
presentation, 3, 6, 12, and 24 months and analyzed.
Results: The median age at diagnosis was 62 years, 17 (53.1%) males and 15 (46.9%) females. The median duration 
of follow‑up was 24 weeks (range, 2‑288 weeks). The average percentage of bone marrow plasmacytosis at diagnosis 
was 38%. Clinical features at presentation were anemia (71.9%) and bone pains (78.1%), while pathological fractures 
were found in 69%, and nephropathy in 13.8%. The longest duration of survival of 288 and 252 weeks were recorded 
in patients on melphalan and prednisolone with or without thalidomide.
Conclusion: Presence of bone pain and anemia in elderly patients should alert the clinician to investigate along the 
lines of MM. Majority of patients have osteolytic lesions on X‑ray and pathological fractures, and benefit from melphalan 
based combinations in situations where facilities for transplant are not available.
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Introduction
Multiple myeloma (MM), a clonal malignancy of plasma 
cells is a common hematological malignancy, currently 
accounting for 13.4% of all hematological cancers, 19% of 
all deaths resulting from hematological malignancies, and 2% 
of all cancer‑related mortality.[1] Studies in Nigeria show that 
MM represents 8.2% of all hematological malignancies.[2] It 
is generally believed that MM starts as a benign monoclonal 
gammopathy of undetermined significance (MGUS),[2] which 
develops further in some cases, to become the asymptomatic 
Smoldering myeloma (SMM) and eventually leading to 
the symptomatic myeloma. The probability of progression 
from MGUS to symptomatic myeloma is 1% per year. On 
the other hand between 10 and 20% of patients with SMM 
progress to symptomatic myeloma per year.[3] Myeloma has 
a higher prevalence in blacks as well as people in the older 
age group, above 60 years.[4] Prior data from the Statistics, 
Epidemiology, and End Results (SEER) program and the 
Multiple Risk Factor Intervention Trial showed consistently 
higher incidence and mortality among blacks.[5,6]
Previous single center studies reported poorer survival 
among African‑American MM patients. In contrast, recent 
data based on MM patients who received autologous 
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transplantation in an equal access healthcare system, 
showed comparable survival between African‑Americans 
and Caucasians, suggesting that the reportedly poorer 
outcome for African‑Americans may be due to inequalities 
in access to modern care. In fact clinicians have been 
cautioned to be aware that the excess mortality rates for 
MM among African‑Americans, to a major degree, is a 
reflection of the fact that MM is two‑ to three‑fold more 
common among African‑Americans.[7] More recent analysis 
have shown that disease‑specific and relative survival rates 
were higher in blacks than whites.[8] In fact, Auner et al., 
set out directly to compare the characteristics and outcome 
of autologous stem cell transplantation (ASCT) for white, 
black, and Asian MM patients.[9] Their findings were that 
patients from the three ethnic groups had similar progression 
free survival (PFS) as well as overall survival (OS), 
supporting the notion that race should not affect decisions 
regarding ASCT for MM.
The clinical features of the illness usually include bone 
pain, which is also a common presentation of other disease 
conditions in this peculiar age group.[4] This leads to delay in 
diagnosis as well as mis‑referrals, which usually in the long 
run affect treatment outcome. A high index of suspicion by 
the physician is therefore important and may be informed 
by knowledge of the common presenting clinical symptoms. 
Evaluation of the common presenting features, especially 
in a resource poor and predominantly black population will 
serve as a guide and necessary aid to early diagnosis.
Raised calcium, renal impairment, anemia, and bone lesions 
(CRAB) symptoms are the currently accepted diagnostic 
criteria for diagnosis of symptomatic (and therefore 
treatable) myeloma.[10,11] Although magnetic resonance 
imaging (MRI) and computed tomography/positron 
emission tomography (CT/PET) are very sensitive and may 
provide more information in certain cases, limited facilities 
as well as finances have limited the use of these diagnostic 
tools in resource poor settings where simple X‑ray of bone 
is still considered standard. Prognostic markers such as, β2 
microglobulin may not be easily assayed in some parts of 
the country or affordable by some patients. However, to the 
unsuspecting physician, these investigations are not usually 
regarded as baseline and the diagnosis is usually delayed till 
complications begin to occur. It may therefore be necessary 
to examine the proportion of patients that actually have 
positive results with these laboratory modalities.
Treatment options in MM have not only been determined to 
be age‑dependent, but current views indicate individualized 
treatment, involving assessment of the genetic mutation 
peculiar to each patient.[12] The non‑availability of facilities 
and specialized personnel for stem cell transplant, contributes 
to the lack of this treatment option to majority of patients. 
The standard of care in myeloma is induction chemotherapy 
with immunomodulatory drugs and proteasome inhibitors 
followed by stem cell transplant. However, in resource 
constrained centers such as ours, most patients still receive 
melphalan based chemotherapy regimen.
This study therefore aims to describe the frequent clinical 
and laboratory features associated with MM at presentation 
in this environment, as well as describe the response to 
various chemotherapeutic combinations commonly used.
Materials and Methods
A retrospective study of 32 patients who were diagnosed 
with MM and managed at the University of Nigeria 
Teaching Hospital, Enugu, Nigeria over a period of 
10 years, January 2002‑2012, were reviewed. Permission 
was obtained from the University of Nigeria Teaching 
Hospital Cancer Registry and Data Collation Institute. 
Clinical presentation and laboratory and radiographic 
data were extracted from patients’ medical records, at 
3 monthly intervals for 2 years post‑diagnosis; poor data 
filing and documentation was a major setback in this study. 
The various chemotherapeutic regimen used and survival 
patterns were analyzed. Only patients who had received 
two or more cycles of chemotherapy or whose duration of 
follow‑up was more than 3 months were included in the 
study. Lack of adequate record keeping and patients being 
lost to follow‑up resulted in small numbers for analysis.
Statistics
Patients’ parameters were analyzed using Statistical Package 
for Social Sciences (SPSS) 10.0 to obtain Spearman’s rho 
correlation coefficient (two‑tailed) between patient survival 
and serum albumin, β2microglobulin, absolute neutrophil 
count, and platelet count at diagnosis. Demographic data 
were explored as expressed in figures.
Results
Thirty‑two patients were assessed; their ages ranged from 
35 to 87 years, with a median age of 62 years. There were 
17 (53.9%) males and 15 (46.1%) females. The median 
duration of follow‑up was 24 weeks (range, 2‑288 weeks). 
The average percentage of bone marrow plasmacytosis at 
diagnosis was 38%, in this patient group.
Table 1 shows some important clinical factors which may 
affect patient survival. The known clinical prognostic 
indicators of poor outcome, such as presence of nephropathy 
and pathological fractures were found more in males at 
presentation. In our study, duration of follow‑up was defined 
as the duration between the day of diagnosis and the last 
day the patient was seen alive. Only about 20% of the 
patients were officially known to have died as at the time 
of review; however these were those who had either died 
in the facility or those whose death had been reported to 
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the hospital. The pitfalls include patients who were lost to 
follow‑up who probably may have died at home without 
formally informing the hospital or caregivers.
The clinical features at presentation were anemia (71.9%) and 
bone pains (78.1%), while complications of myeloma such as 
pathological fractures were found in 69% and nephropathy 
in 13.8% of the patients. Laboratory abnormalities 
were observed at diagnosis. The median hemoglobin 
concentration (Hb) at diagnosis was 8.5 g/dL, total white 
blood cell (WBC) count 5.85 × 109/L, platelet count 
192.5 × 109/L, and absolute neutrophil count 3.1 × 109/L. 
The median values of other results at diagnosis were: 
Serum globulin 4.95 g/L (range 2.1‑11.9), albumin 3.8 g/L 
(range 1.9‑5.2), β2 microglobulin 4.0 µg/mL (range 2‑11), 
and calcium 2.5 mmol/L (range 2.1‑9.6), and phosphate 
1.35 mmol/L (range 0.8‑8.6). The median values of other 
results at diagnosis were immunoglobulin (Ig) G 0.88 µg/mL 
(range 0.32‑0.89), IgA 0.4 µg/mL (range 0.12‑0.64), IgM 
0.37 µg/mL (range 0.04‑0.78).
With regards to the chemotherapeutic regimen used, 22.2% 
of the patients were placed on melphalan/prednisolone (MP), 
29.6% on melphalan/prednisolone/thalidomide (MPT), 
14.8% on cyclophosphamide/vincristine/adriamycin/
prednisolone (CVAP), 14.8% on melphalan alone, 7.4% 
on bortezomib based combinations, while 11.1% received 
no anticancer agents. Higher mortality rates were recorded 
in patients on MP and MPT, though this regimen was used 
for majority of the patients. Some of the patients were 
not placed on any regimen as at the last visit. These were 
patients who were lost to follow‑up or who due to several 
co‑morbidities could not be commenced on cytotoxic 
chemotherapy.
Table 2 contains the correlation coefficient (Spearman rho 
and Kendall tau_b) and P values for the various clinical 
and laboratory parameters in the patients reviewed. This 
shows no significant correlation between treatment outcome 
with regards to duration of follow‑up and any of the clinical 
and laboratory parameters. The number of cases recorded 
for β2 microglobulin was too low to be analyzed with the 
Spearman correlation. International staging system (ISS) 
for myeloma for few of the patients (eight people) in this 
group revealed that 37.5% of the patients were in the high 
and intermediate risk group each, while 25% were in the low 
risk group. Majority of the patients (24 people) were staged 
using the Durie and Salmon staging and revealed; 53.6% in 
stage III, 17.9% stage II, and 28.6% stage I.
The median follow‑up time was 24 weeks (6 months), range 
2‑288 weeks. The longest duration of follow‑up of 288 and 
252 weeks were recorded in patients on MP and had died 
while on admission, and another who had asymptomatic 
myeloma and was not on treatment up until the time of 
this write up. There was no significant correlation between 
patient survival and chemotherapeutic regimen used, serum 
albumin, β2 microglobulin, calcium, presence of pathological 
fractures, or nephropathy. However, these values were 
obtained at diagnosis and subsequent values post diagnosis 
Table 1: Frequency of occurrence of some important 
clinical and laboratory factors
Features Presence of this 
feature (%)
Yes No
Presence of co‑morbidities (n=26) 16 (61.5) 10 (38.5)
Bone pain at diagnosis (n=29) 25 (86.2) 4 (13.8)
Pathological fracture at 
diagnosis (n=28)
17 (69) 11 (31)
Anemia at diagnosis (n=26) 22 (78.9) 4 (21.1)
Nephropathy at diagnosis (n=27) 4 (13.8) 25 (86.2)
Bence Jones proteinuria (n=12)  9 (47.4)  10 (52.6)
Serum β
2
 microglobulin at 
diagnosis>3.5 mg/dL
5 (71.4) 2 (28.6)
Serum albumin at 
diagnosis>3.5 g/dL (n=23)
14 (60.9) 9 (39.1)
Immunoglobulin (m protein) type IgA 5 (45.5) Others (54.5)
Thickened gamma band on 
electrophoresis (n=18)
17 (89.5) 2 (10.5)
Osteolytic lesions on X‑ray (n=15) 11 (73.3) 4 (26.7)
“Punched out” lesions on skull 
X‑ray (n=14)
7 (50) 7 (50)
Presence of amyloidosis (n=15) 0 (0) 15 (100)
Clinical evidence of 
hyperviscosity (n=13)
3 (23.1) 10 (76.9)
Table 2: Patient survival and correlation with clinical 
and laboratory factors
P value Spearman 
rho 
(2-tailed)
P value Kendall 
tau_b 
(2-tailed)





NA NA 0.871 −0.040




0.474 0.186 0.456 0.157
White blood cell 
count at diagnosis
0.626 0.102 0.616 0.085
Platelet count at 
diagnosis




0.887 0.029 0.884 0.029
Presence of 
nephropathy
0.357 −0.184 0.347 −0.184
Chemotherapeutic 
regimen used
0.162 −0.325 0.156 −0.291
Age at diagnosis NA NA 0.774 −0.045
Durie and Salmon 
Staging
NA NA 0.864 0.032
NA=Not available (could not be analyzed)
Madu, et al.: Presentation and outcomes in myeloma
215Nigerian Journal of Clinical Practice • Mar-Apr 2014 • Vol 17 • Issue 2
which may show a positive relationship, were not accessible. 
Figure 1a is the Kaplan‑Meier survival curve for all the 
patients, and indicates that the fatalities were encountered 
as from the around the 10th week of management. Figure 1b 
shows the survival curve of males versus females and 
indicates that mortality in males seems to be more between 
the weeks 120 and 180 (2.5‑3.5 years). Figure 2 illustrates 
the various chemotherapeutic combinations given the 
patients. Most of the patients received combinations 
containing melphalan.
Discussion
The median age at diagnosis of myeloma in this patient 
group was 62 years. This is similar to studies done in other 
Nigerian centers. In Ile‑Ife, western Nigeria where a median 
age of 60 years was obtained, while Omoti and Omuemu, in 
Benin City south western Nigeria, got a slightly lower age 
of 54 years.[13,14] Initial complaints in MM consist mainly of 
bone pains, which is also a common presenting feature of 
several diseases of old age. Majority of the patients in this 
study had bone pains and this is similar to the findings of 
previous studies.[4,10] However, in the older age group this 
will need to be further evaluated to rule out myeloma as well 
as other diseases of the elderly. Physicians should bear this in 
mind as a leading cause of delayed presentation or referrals.
Anemia occurring also in this background of bone pains 
is another frequent presenting feature. This finding is 
similar to that reported by Fasola et al., Omoti et al., and 
Riccardi et al., who noted in their various reports that the 
presenting features of low hemoglobin concentration such 
as weakness, dizziness, and fainting feeling in the elderly 
are common presenting features.[13,15] This presentation is 
of more importance in resource‑poor settings where the 
clinical acumen rather than diagnostic facilities are relied 
upon. Most of our patients have with stage II or III disease 
at diagnosis, indicative of late presentation or aggressive 
disease. Unlike in developed countries where diagnosis is 
usually made during evaluation of anemia detected during 
routine evaluation, in Nigeria, there are no routine healthy 
adult yearly evaluation and hence patients present with 
symptomatic and with more advanced disease. This may 
partly explain the poor outcome.
There was a high incidence of pathological fracture amongst 
this patient group. Majority of these fractures were clinically 
discernable, while the others were diagnosed on plain 
Figure 2: Patient survival on the different chemotherapeutic regimen
Figure 1: (a) Kaplan‑Meier survival curve for all myeloma patients, (b) Kaplan‑Meier survival curve for the different sexes
ba
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radiograph. This is similar to the findings by Salawu et al., 
who observed pathological fractures in 44% of their myeloma 
patients in Ile‑Ife, western Nigeria. This is another preventable 
consequence of late presentation and majority of the patients 
were initially seen and referred from the Orthopedic Unit. 
Bone pain usually precedes fracture in myeloma and early 
diagnosis may prevent this debilitating complication if a high 
index of suspicion is maintained. Fracture in myeloma is 
associated with increased morbidity and poorer prognosis.[10] 
Therefore, efforts to avert this complication will definitely 
improve treatment outcome. MM therefore should be ruled 
out in any adult or elderly patient with a history of chronic 
bone pain. Majority of the patients did not have renal 
impairment at presentation. This has been known to adversely 
affect treatment outcome. This is similar to figures obtained 
in other studies on nephropathy in myeloma done in Nigeria, 
where 36% had renal impairment compared to 16% in this 
study. However, in the Ibadan study the serum electrolytes, 
urea, and creatinine were used to estimate glomerular filtration 
rate and renal impairment; while in this study only those 
patients with clinical diagnosis renal failure (chronic kidney 
disease) were recorded.[16] Causes of nephropathy in myeloma 
such as hypercalcemia, amyloidosis, severe hyperproteinemia, 
and hyperviscosity were also noted to be absent in majority of 
the patients at diagnosis.
Laboratory investigations as well as radiological tests are 
the mainstay of diagnosis of MM. However, in a resource 
poor setting with limited funds and access to facility for 
in‑depth investigation, physicians should be aware of the 
most frequently positive diagnostic tests. Presence of Bence 
Jones proteinuria was found to occur infrequently (47.4%) 
in this patient group, though gammopathy on serum protein 
electrophoresis was quite rife (89.5%). Similar figures were 
also observed by Salawu et al. Anemia was also another 
common presenting feature as well as osteolytic bone lesions 
on plain radiograph. These represent simple and affordable 
diagnostic tools which may further inform the choice of early 
referral. However, “punched out” skull lesions were observed 
in only half of the patients. Reversal of the albumin/globulin 
ratio was another commonly observed presenting feature 
in this patient group and had previously described in other 
studies. However, some disease features such as amyloidosis 
and symptoms of hyperviscosity has been found to be quite 
rare and may not be easily found at presentation.
The relationship between patient survival and serum 
albumin, β2‑microglobulin, platelet count, absolute 
neutrophil, and WBC count did not reveal any significant 
correlation. Also presence of pathological fracture or 
nephropathy did not significantly affect survival as had been 
previously suggested by Talamo et al.
The median follow‑up time in this group of patients was 
24 weeks (6 months). However, majority of the patients 
in this group were still alive as at the time of analysis and 
repeat assessment after several years may eventually show 
a relationship. There was also no significant difference in 
duration of treatment and the type of chemotherapeutic 
combination used. Most of the patients were placed on 
melphalan and prednisolone based regimen. The choice 
of chemotherapy was not randomized, but was based on 
patients’ performance score and presence of co‑morbidities. 
Although being a retrospective study, analysis of response 
to treatment may not be optimal, however some insight 
can be obtained as with regards to the effectiveness of 
chemotherapeutic combinations.
Therefore, in a resource poor setting investigations should 
be targeted at those parameters with a high frequency of 
positivity and greater diagnostic power in order to avert 
debilitating complications and improve survival. Larger 
studies in resource poor settings may be necessary with the 
aim of generating a need based diagnostic and treatment 
algorithm, peculiar to these environments.
Conclusion
Bone pain and anemia in the elderly patients are important 
clinical signs which should alert the clinician in a resource 
poor setting to investigate along the lines of MM. Majority 
of the patients will present with osteolytic lesions on X‑ray 
and pathological fractures, though skull radiograph may not 
show the typical lesions. Gammopathy on serum protein 
electrophoresis is more likely to turn out positive than Bence 
Jones proteinuria.
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